About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Debt
Debt-to-Equity Ratio0.03%
Current Ratio3.87%
Quick Ratio3.87%
Price-To-Earnings
Trailing P/E Ratio-14.65
Forward P/E Ratio-9.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.41 million
Price / Sales18.73
Cash FlowN/A
Price / CashN/A
Book Value$1.08 per share
Price / Book6.28
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-116.17%
Return on Equity-42.52%
Return on Assets-32.70%
Miscellaneous
Employees93
Outstanding Shares86,790,000
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its quarterly earnings results on Friday, February, 9th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.04. The biotechnology company earned $3.51 million during the quarter, compared to analysts' expectations of $8.71 million. Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 analysts have issued 12-month target prices for Arrowhead Pharmaceuticals' shares. Their predictions range from $4.00 to $10.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $6.30 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
- 2. Cantor Fitzgerald analysts commented, "Arrowhead reiterated its recently disclosed timeline for returning to clinical development with at least two indications (AAT and HBV) in 1H18." (9/25/2017)
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX), Epizyme (EPZM), TG Therapeutics (TGTX), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), CytomX Therapeutics (CTMX), Athenex (ATNX), Zai Lab (ZLAB), Uniqure (QURE), MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB) and Alder BioPharmaceuticals (ALDR).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
- Dr. Bruce D. Given, Chief Operating Officer (Age 64)
- Mr. Patrick O'Brien, Gen. Counsel (Age 54)
- Dr. Mark M. Davis Ph.D., Founder and Founder & Director of Insert Therapeutics Inc & Calando
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
News articles about ARWR stock have been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a news impact score of 0.25 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 44.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $6.78.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $604.91 million and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Arrowhead Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.30, suggesting that the stock has a possible downside of 7.08%. The high price target for ARWR is $10.00 and the low price target for ARWR is $4.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.67 | 2.50 | 2.33 | 2.20 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.30 | $4.70 | $3.1250 | $2.00 |
| Price Target Upside: | 7.08% downside | 15.62% downside | 50.32% downside | 43.66% downside |
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Consensus Price Target History
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 26.85%
Arrowhead Pharmaceuticals (NASDAQ ARWR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/27/2018 | Kenneth Allen Myszkowski | CFO | Sell | 20,000 | $8.00 | $160,000.00 | 330,815 |  |
| 3/15/2018 | Christopher Richard Anzalone | CEO | Sell | 300,000 | $7.43 | $2,229,000.00 | 2,194,789 | |
| 3/13/2018 | Christopher Richard Anzalone | CEO | Sell | 100,000 | $7.43 | $743,000.00 | 2,194,789 | |
| 3/5/2018 | Bruce D Given | COO | Sell | 20,000 | $6.73 | $134,600.00 | 908,356 | |
| 1/1/2018 | Bruce D Given | COO | Sell | 20,000 | $3.69 | $73,800.00 | 948,356 | |
| 10/14/2016 | Douglas B. Given | Director | Sell | 12,000 | $6.72 | $80,640.00 | | |
| 8/23/2016 | Kenneth Allen Myszkowski | CFO | Sell | 6,900 | $8.00 | $55,200.00 | 128,789 | |
| 8/22/2016 | Kenneth Allen Myszkowski | CFO | Sell | 13,100 | $8.00 | $104,800.00 | 128,789 | |
| 12/30/2015 | Kenneth Allen Myszkowski | CFO | Sell | 23,347 | $6.13 | $143,117.11 | 135,000 | |
| 10/28/2015 | Mauro Ferrari | Director | Buy | 400 | $7.62 | $3,048.00 | | |
| 10/9/2015 | Mauro Ferrari | Director | Buy | 1,900 | $6.19 | $11,761.00 | | |
| 1/5/2015 | David L Lewis | Insider | Sell | 15,000 | $8.01 | $120,150.00 | | |
| 10/15/2014 | Christopher Richard Anzalone | CEO | Buy | 16,000 | $6.32 | $101,120.00 | | |
| 10/1/2014 | Charles Mckenney | Director | Sell | 2,500 | $14.70 | $36,750.00 | | |
| 9/30/2014 | David L Lewis | Insider | Sell | 15,000 | $15.02 | $225,300.00 | | |
| 9/26/2014 | Douglas B Given | Director | Sell | 2,000 | $15.24 | $30,480.00 | | |
| 6/9/2014 | Charles Mckenney | Director | Sell | 22,000 | $14.32 | $315,040.00 | | |
| 2/12/2014 | Kenneth Allen Myszkowski | CFO | Sell | 16,000 | $18.77 | $300,320.00 | | |
| 2/7/2014 | Edward W Frykman | Director | Sell | 3,148 | $15.98 | $50,305.04 | | |
(Data available from 1/1/2013 forward)
Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines
| Source: |
|
Arrowhead Pharmaceuticals (NASDAQ:ARWR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Income Statement, Balance Sheet and Cash Flow Statement
Arrowhead Pharmaceuticals (NASDAQ ARWR) Stock Chart for Monday, April, 23, 2018
Loading chart…
